Inflammatory Bowel Disease: Crohn Disease vs Ulcerative Colitis

Inflammatory bowel disease (IBD) encompasses two primary chronic inflammatory conditions affecting the gastrointestinal tract: Crohn disease (CD) and ulcerative colitis (UC). These distinct entities share common features but differ significantly in their pathophysiology, distribution, and clinical manifestations.

[KEY_CONCEPT] Crohn disease is a transmural, granulomatous inflammatory condition that can affect any portion of the GI tract from mouth to anus, characterized by skip lesions and a predilection for the terminal ileum and proximal colon. The inflammation extends through all layers of the bowel wall, leading to complications such as strictures, fistulas, and abscesses.

Ulcerative colitis is a mucosal and submucosal inflammatory condition limited to the colon and rectum, typically presenting with continuous inflammation starting from the rectum and extending proximally in a circumferential pattern.

Epidemiological Features

[HIGH_YIELD] The incidence of IBD has been steadily increasing globally, with the highest rates observed in North America and Northern Europe. Both conditions demonstrate significant genetic predisposition, with over 200 susceptibility loci identified through genome-wide association studies.

The clinical presentation of IBD varies significantly between CD and UC, reflecting their distinct anatomical distributions and inflammatory patterns.

Crohn Disease Clinical Features

Gastrointestinal symptoms:

• Abdominal pain (typically right lower quadrant due to ileocolic involvement)
• Diarrhea (usually non-bloody, 3-5 stools/day)
• Weight loss and malnutrition (more common than in UC)
• Perianal disease (skin tags, fissures, fistulas, abscesses)

Extraintestinal manifestations:

• Arthritis (peripheral and axial)
• Ocular complications (episcleritis, uveitis)
• Dermatologic manifestations (erythema nodosum, pyoderma gangrenosum)
• Hepatobiliary complications (primary sclerosing cholangitis, cholelithiasis)

[CLINICAL_PEARL] Perianal disease occurs in approximately 30-50% of CD patients and may be the presenting feature, often preceding intestinal symptoms by months to years.

Ulcerative Colitis Clinical Features

Gastrointestinal symptoms:

• Bloody diarrhea (hallmark symptom)
• Tenesmus and urgency
• Lower abdominal cramping (left-sided)
• Mucus in stool
• Constitutional symptoms during flares (fever, weight loss)

Disease extent classification:

• Proctitis (rectum only): 25-30% of cases
• Left-sided colitis (rectum to splenic flexure): 30-40%
• Pancolitis (entire colon): 20-30%

[HIGH_YIELD] Toxic megacolon is a life-threatening complication more commonly associated with UC, presenting with abdominal distension, systemic toxicity, and colonic dilation >6 cm on imaging.

Pediatric Considerations

Both conditions can present in childhood, with CD more commonly affecting the terminal ileum and UC showing more extensive colonic involvement in pediatric patients [3]. Growth failure and delayed puberty are significant concerns in pediatric IBD, particularly in CD due to malabsorption and chronic inflammation.

The diagnosis of IBD requires a comprehensive approach combining clinical presentation, laboratory studies, imaging, and endoscopic evaluation with histopathology [6].

Diagnostic Algorithm

Suspected IBD (chronic diarrhea, abdominal pain, weight loss) ↓

1. Initial Assessment
   • Complete history & physical examination
   • Laboratory studies (CBC, CRP, ESR, albumin, B12, folate)
   • Stool studies (culture, C. diff, parasites, calprotectin) ↓
2. Imaging Studies
   • CT enterography or MR enterography (if small bowel involvement suspected)
   • Abdominal CT (if acute complications suspected) ↓
3. Endoscopic Evaluation
   • Colonoscopy with ileoscopy + biopsies
   • Upper endoscopy (if CD suspected) ↓
4. Histopathological Confirmation
   • Multiple biopsies from affected and unaffected areas
   • Evaluate for granulomas, crypt architecture, inflammation pattern ↓
5. Final Diagnosis: CD vs UC vs IBD-Unclassified

Endoscopic Features Comparison

Histopathological Criteria

Crohn Disease:

• Transmural inflammation
• Non-caseating granulomas (present in 25-50%)
• Skip lesions microscopically
• Fissuring ulcers
• Lymphoid aggregates

Ulcerative Colitis:

• Mucosal and submucosal inflammation only
• Crypt abscesses and distortion
• Continuous inflammation
• Surface epithelial damage
• Increased chronic inflammatory cells in lamina propria

[HIGH_YIELD] Fecal calprotectin is a highly sensitive marker for intestinal inflammation, with levels >250 μg/g strongly suggestive of IBD and useful for monitoring disease activity and treatment response.

[CLINICAL_PEARL] Approximately 10-15% of IBD cases cannot be definitively classified as CD or UC and are labeled as IBD-unclassified (IBD-U) or indeterminate colitis.

Management of IBD follows a step-up approach tailored to disease severity, extent, and phenotype, with the goal of achieving and maintaining clinical and endoscopic remission [2].

Treatment Goals (STRIDE-II Targets)

[KEY_CONCEPT] Treat-to-Target approach emphasizes:

• Clinical remission (resolution of symptoms)
• Endoscopic healing (mucosal healing)
• Histologic remission (normalization of inflammatory markers)
• Quality of life improvement
• Prevention of complications

Induction Therapy by Disease Severity

Mild-Moderate Disease

Ulcerative Colitis:

• 5-ASA compounds (mesalamine): first-line therapy
  • Oral: 2.4-4.8 g/day divided doses
  • Topical (suppositories/enemas): for left-sided disease
• Topical corticosteroids for refractory cases

Crohn Disease:

• Budesonide (ileal-release): 9 mg daily × 8 weeks
• Conventional systemic steroids if extensive small bowel involvement
• Exclusive enteral nutrition (EEN): first-line in pediatric CD [1]

Moderate-Severe Disease

Both CD and UC:

• Systemic corticosteroids: prednisolone 0.75-1 mg/kg/day (max 40-60 mg)
• Anti-TNF therapy: infliximab, adalimumab, certolizumab
• Anti-integrin therapy: vedolizumab (gut-selective)
• JAK inhibitors: tofacitinib (UC), upadacitinib (CD and UC)

Maintenance Therapy Algorithm

Achieved Remission ↓ Steroid-induced remission? ↓ ↓ YES NO ↓ ↓ Initiate Continue maintenance: induction agent

• 5-ASA (UC) at reduced dose
• Thiopurines
• Biologics
• JAK inhibitors

Immunomodulators

[HIGH_YIELD] Biologic therapy is increasingly used as first-line treatment in patients with high-risk features: extensive disease, deep ulcerations, early age of onset, perianal disease, or steroid dependence.

Surgical Considerations

Indications for surgery:

Crohn Disease [2]:

• Stricturing disease with obstruction
• Penetrating complications (fistulas, abscesses)
• Refractory perianal disease
• Failed medical therapy
• Growth failure in pediatric patients

Ulcerative Colitis:

• Acute severe colitis unresponsive to medical therapy
• Toxic megacolon
• Refractory chronic disease
• Dysplasia or malignancy

[CLINICAL_PEARL] Ileocolic resection is the most common surgical procedure for CD, with endoscopic recurrence rates of 60-70% at one year post-operatively, emphasizing the need for prophylactic medical therapy.

IBD patients require lifelong monitoring for disease complications, medication side effects, and malignancy surveillance.

Major Complications by Disease Type

Crohn Disease Complications

Intestinal complications:

• Strictures (fibrostenotic): 30-50% of patients
• Fistulas (enterocutaneous, enteroenteric, perianal): 20-40%
• Abscesses (intra-abdominal, perianal)
• Perforation (free or contained)
• Small bowel obstruction

Nutritional complications:

• Vitamin B12 deficiency (ileal resection/disease)
• Fat-soluble vitamin deficiencies (A, D, E, K)
• Iron deficiency anemia
• Protein-energy malnutrition [4]

Ulcerative Colitis Complications

Acute complications:

• Toxic megacolon (5-10% of patients)
• Severe hemorrhage
• Perforation (rare, usually with toxic megacolon)

Chronic complications:

• Colorectal cancer (increased risk with pancolitis, long duration)
• Primary sclerosing cholangitis (5-10% of UC patients)
• Strictures (typically malignant until proven otherwise)

Malignancy Surveillance

[HIGH_YIELD] Colorectal cancer surveillance recommendations:

• Screening colonoscopy 8-10 years after IBD diagnosis
• Surveillance intervals:
  • High-risk patients: annually
  • Average-risk patients: every 2-3 years
  • Low-risk patients: every 5 years

Risk stratification:

• High risk: PSC, family history of CRC, extensive colitis with severe inflammation
• Average risk: extensive colitis without high-risk features
• Low risk: left-sided UC or Crohn colitis

Monitoring Parameters

Laboratory Monitoring

Medication-Specific Monitoring

Thiopurine monitoring:

• TPMT genotyping/phenotyping before initiation
• CBC weekly × 4 weeks, then every 3 months
• 6-TGN and 6-MMP levels if treatment failure or toxicity

Anti-TNF monitoring:

• Tuberculosis screening (chest X-ray, IGRA/TST)
• Hepatitis B/C screening
• CBC and LFTs every 3-6 months
• Anti-drug antibody levels if treatment failure

[CLINICAL_PEARL] Pouchitis occurs in 40-50% of UC patients following ileal pouch-anal anastomosis (IPAA), with acute episodes typically responding to antibiotic therapy [5].

Pregnancy Considerations

Key principles:

• Active disease poses greater risk than medications
• Most IBD medications are safe in pregnancy (except methotrexate)
• Fertility may be reduced in active disease
• Delivery mode depends on perianal disease activity in CD

The prognosis of IBD varies significantly based on disease phenotype, extent, response to therapy, and development of complications. Long-term outcomes have improved substantially with earlier diagnosis and advanced therapeutic options.

Disease Course Patterns

Crohn Disease Natural History

Behavior evolution over time:

• Inflammatory (B1): 80% at diagnosis → 50% at 10 years
• Stricturing (B2): 10% at diagnosis → 30% at 10 years
• Penetrating (B3): 10% at diagnosis → 20% at 10 years

[HIGH_YIELD] Montreal Classification predicts prognosis:

• Age at diagnosis <17 years (A1) associated with more aggressive disease
• Ileocolonic location (L3) higher risk of complications
• Perianal disease modifier (p) indicates more complex disease course

Ulcerative Colitis Natural History

Disease extent progression:

• Proctitis: 10-30% extend proximally over time
• Left-sided colitis: 10-20% progress to pancolitis
• Pancolitis: rarely regresses in extent

Long-term Outcomes

Surgical Rates

[CLINICAL_PEARL] Post-operative recurrence in CD is nearly universal endoscopically (70-90% at 1 year), but clinical recurrence occurs in 30-50% of patients within 5 years of surgery [2].

Quality of Life Factors

Factors associated with better outcomes:

• Early diagnosis and treatment
• Adherence to therapy
• Smoking cessation (particularly important in CD)
• Psychological support and counseling
• Nutritional optimization
• Regular monitoring and surveillance

Factors associated with worse outcomes:

• Smoking (CD)
• Young age at onset
• Extensive disease
• Corticosteroid dependence
• Malnutrition
• Psychological comorbidities

Follow-up Care Framework

Routine Monitoring Schedule

Stable disease (remission):

• Clinical visits: Every 3-6 months
• Laboratory monitoring: Every 3-6 months
• Endoscopic assessment: Every 1-3 years based on risk
• Bone density screening: Every 2-3 years if steroid exposure

Active disease:

• Clinical visits: Every 4-8 weeks
• Laboratory monitoring: Monthly until stable
• Endoscopic reassessment: 3-6 months after treatment changes

Preventive Care

Vaccinations:

• Annual influenza vaccine
• Pneumococcal vaccine (PCV13 and PPSV23)
• Hepatitis A and B vaccines if not immune
• Live vaccines contraindicated with immunosuppression

Bone health:

• Calcium and vitamin D supplementation
• DEXA scan if prolonged steroid use or multiple risk factors
• Bisphosphonates if osteoporosis diagnosed

Cancer screening:

• Colonoscopic surveillance as outlined above
• Cervical cancer screening (increased risk with immunosuppression)
• Skin cancer screening (particularly with thiopurines)

[KEY_CONCEPT] Patient education is crucial for long-term management success, including recognition of flare symptoms, medication adherence, lifestyle modifications, and when to seek urgent care.

Emerging Therapies and Future Directions

The therapeutic landscape for IBD continues to evolve with novel targets including IL-23 inhibitors, sphingosine-1-phosphate receptor modulators, and selective JAK inhibitors. Personalized medicine approaches using genetic markers, therapeutic drug monitoring, and microbiome analysis hold promise for optimizing treatment selection and outcomes.